Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Thompson

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
European Urology|April 21, 2023
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without OrteronelPrimo N Lara, Edward Mayerson, Erik Gertz, et al.
JAMA Network Open|July 9, 2024
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 TrialGeorges Gebrael, Yeonjung Jo, Umang Swami, et al.
The Journal of Urology|January 16, 2007
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomesMichael S Cookson, Gunnar Aus, Arthur L Burnett, et al.
The Journal of Urology|May 19, 2007
Guideline for the management of clinically localized prostate cancer: 2007 updateIan Thompson, James Brantley Thrasher, Gunnar Aus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Can urinary PCA3 supplement PSA in the early detection of prostate cancer?John T Wei, Ziding Feng, Alan W Partin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2024
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate CancerSusan Halabi, Akash Roy, Larysa Rydzewska, et al.
The Journal of Urology|June 16, 2007
Erectile function outcome reporting after clinically localized prostate cancer treatmentArthur L Burnett, Gunnar Aus, Edith D Canby-Hagino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2024
Reply to J.A. Garcia et alSusan Halabi, Siyuan Guo, Akash Roy, et al.
JAMA Network Open|October 7, 2024
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate CancerAmir Goldkorn, Catherine Tangen, Melissa Plets, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 26, 2015
CD14++CD16+ Monocytes Are Enriched by Glucocorticoid Treatment and Are Functionally Attenuated in Driving Effector T Cell ResponsesBaoying Liu, Ashwin Dhanda, Sima Hirani, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
European Urology|April 21, 2023
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without OrteronelPrimo N Lara, Edward Mayerson, Erik Gertz, et al.
JAMA Network Open|July 9, 2024
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 TrialGeorges Gebrael, Yeonjung Jo, Umang Swami, et al.
The Journal of Urology|January 16, 2007
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomesMichael S Cookson, Gunnar Aus, Arthur L Burnett, et al.
The Journal of Urology|May 19, 2007
Guideline for the management of clinically localized prostate cancer: 2007 updateIan Thompson, James Brantley Thrasher, Gunnar Aus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Can urinary PCA3 supplement PSA in the early detection of prostate cancer?John T Wei, Ziding Feng, Alan W Partin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2024
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate CancerSusan Halabi, Akash Roy, Larysa Rydzewska, et al.
The Journal of Urology|June 16, 2007
Erectile function outcome reporting after clinically localized prostate cancer treatmentArthur L Burnett, Gunnar Aus, Edith D Canby-Hagino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2024
Reply to J.A. Garcia et alSusan Halabi, Siyuan Guo, Akash Roy, et al.
JAMA Network Open|October 7, 2024
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate CancerAmir Goldkorn, Catherine Tangen, Melissa Plets, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 26, 2015
CD14++CD16+ Monocytes Are Enriched by Glucocorticoid Treatment and Are Functionally Attenuated in Driving Effector T Cell ResponsesBaoying Liu, Ashwin Dhanda, Sima Hirani, et al.
Pageof 11